In addition, CD13-targeted therapies would likely broadly benefit patients with various types of myeloid malignancies [39], in particular for those with lower survival rate, such as acute myeloid leukemia, the most common acute leukemia in adults, with 17% survival rate at 5 years. Here, ANPEP is linked to acute myeloid leukemia.